Development of a polyclonal antibody with defined specificity against synthetic peptides from the N-myc oncoprotein using multiple antigen peptide and hemocyanin conjugation methods

Journal of Pediatric Surgery

Volumn 34, Issue 3, 1999, Pages 454-460

  Yang, Hong Wei ^b   Ikeda, Hitoshi ^b   Kato, Kanefusa ^b   Nakagawara, Akira ^b   Choi, Seung Hoon ^b   Hayashi, Yasuhida ^b   Obana, Kazuko ^b   Hemmi, Hiromichi ^b   Tsuchida, Yoshiaki ^a  

^a Gumna Children S Medical Center   (Japan)

^b NONE

Author keywords

Anti N Myc oncoprotein antibody; Multiple antigen peptide method; Neuroblastoma; Synthetic peptide

Indexed keywords

HEMOCYANIN; IMMUNOGLOBULIN G; ONCOPROTEIN; POLYCLONAL ANTIBODY;

ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ARTICLE; GENE AMPLIFICATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LUNG SMALL CELL CANCER; NEUROBLASTOMA; ONCOGENE C MYC; ONCOGENE MYC; PRIORITY JOURNAL; RABBIT; RISK FACTOR;

EID: 0033016889     PISSN: 00223468     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3468(99)90498-0     Document Type: Article

References (25)

1. Brodeur GM, Seeger RC, Schwab M, et al: Amplification of N-myc in untreated human neuroblastoma correlates with advanced stage disease. Science 244:1121-1124, 1984
2. Tsuchida Y, Hemmi H, Inoue A, et al: Genetic clinical markers of human neuroblastoma with special reference to N-myc oncogene: Amplified or not amplified? Tumor Biol 17:65-74, 1996
3. Seeger RC, Brodeur GM, Sather H, et al: Association of multiple copies of N-myc oncogene with rapid progression of neuroblastoma. N Engl J Med 313:1111-1116, 1985
4. Suita S, Zaizen Y, Kaneko M, et al: What is the benefit of aggressive chemotherapy for advanced neuroblastoma with N-myc amplification? A report from the Japanese Study Group for the Treatment of Advanced Neuroblastoma. J Pediatr Surg 29:746-750, 1994
5. Kaneko M, Nishihira H, Mugishima H, et al: Stratification of treatment of stage 4 neuroblastoma patients based on N-myc amplification status. Med Pediatr Oncol 31:1-7, 1998
6. Cohn SL, Salwen H, Quasney NW, et al: Prolonged N-Myc protein halflife in a neuroblastoma cell line lacking N-myc amplification. Oncogene 5:1821-1827, 1990
7. Wada RK, Seeger RC, Brodeur GM, et al: Human neuroblastoma cell lines that express N-myc without gene amplification. Cancer 72:3346-3354, 1993
8. Hiyama E, Hiyama K, Yokoyama T, et al: Immunohistochemical analysis of N-Myc protein expression in neuroblastoma: Correlation with prognosis of patients. J Pediatr Surg 26:838-843, 1991
9. Raschella G, Romeo A, Negroni A, et al: Lack of correlation between N-myc and MAX expression in neuroblastoma tumors and in cell lines: Implication for N-Myc-MAX complex formation. Cancer Reg 54:2251-2255, 1994
10. Gomez-Lahoz E, Xu L, Schreiber-Agus N, et al: Suppression of Myc, but not Ela, transformation activity by Max-associated proteins, Mad and Mxil. Proc Natl Acad Sci USA 91:5503-5507, 1994
11. Brodeur GM, Pritchard J, Berthold F, et al: Revision of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466-1477, 1993
12. Cohn SL, Look AT, Joshi VV, et al: Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: A Pediatric Oncology Group study. Cancer Res 55:721-726, 1995
13. Hemmi H, Yamada K, Yoon U, et al: Coexpression of the myc gene family members in human neuroblastoma cell lines. Biochem Mol Biol Int 36:1135-1141, 1995
14. Tam JP, Zavala F: Multiple antigen peptide: A novel approach to increase detection sensitivity of synthetic peptides in solid-phase immunoassay. J Immunol Method 124:53-61, 1989
15. Briand JB, Barin C, Van Regenmortel MHV, et al: Application and limitations of the multiple antigen peptide (MAP) system in the production and evaluation of anti-peptide and anti-protein antibodies. J Immunol Method 156:255-265, 1992
16. Takahashi T, Obata Y, Sekido Y, et al: Expression and amplification of myc gene family in small cell lung cancer and its relationship to biological characteristics. Cancer Res 49:2683-2688, 1989
17. Sekido Y Takahashi T, Mäkelä TP, et al: Complex intrachromosomal rearrangement in the process of amplification of the L-myc gene in small-cell lung cancer. Mol Cell Biol 12:1747-1754, 1992
18. Tsuchida Y, Kanda N, Shimatake H, et al: Clinical significance of gene amplification studied in human neuroblastoma xenografts: Relationship with tumor growth rate, chemotherapeutic sensitivities and levels of neuron-specific enolase. Exp Cell Biol 56:277-284, 1988
19. Fanidi A, Harrington EA, Evan GI: Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 359:554-556, 1992
20. Littlewood TD, Amati B, Land H, et al: Max and c-Myc/Max DNA-binding activity in cell extracts. Oncogene 7:1782-1792, 1992
21. Ikegaki N, Bukovsky J, Kennett RH: Identification and characterization of the N-myc gene product in human neuroblastoma cells by monoclonal antibody with defined specificities. Proc Natl Acad Sci U S A 83:5929-5933, 1986
22. Ikegaki N, Polakova K, Prince L, et al: Expression and localization of the N-Myc protein in human neuroblastoma cells: Analysis of the effect of gamma interferon treatment and distribution of the N-Myc protein in the nucleus, in Evans AE (ed): Advances in Neuroblastoma Research 2, New York, NY, Alan R Liss, 1988, pp 133-144
23. Slamon DJ, Boone TC, Seeger RC, et al: Identification and characterization of the protein encoded by the human N-myc oncogene. Science 232:768-772, 1986
24. Nakagawa C, Tsukahara T, Shimatake H: Genetic engineering of human N-Myc oncoprotein and the production of and human N-Myc protein antibody. J Med Soc Toho 36:207-216, 1989
25. Yang HW, Hemmi H, Zhong X, et al: Water-soluble recombinant N-Myc protein expressed in Escherichia coli. Cancer J 10:285-290, 1997